JAZZ PHARMACEUTICALS FRANCE
- Country
- π«π·France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02607904
- Locations
- πͺπΈ
Hospital Ruber Internacional, Madrid, Spain
πͺπΈHospital Universitario Virgen del Rocio, Sevilla, Spain
π³π±SEIN - Epilepsy Institute in the Netherlands Foundation, Zwolle, Netherlands
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02565108
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT02564952
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT02544750
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- Conditions
- SeizuresTuberous Sclerosis Complex
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT02544763
- Locations
- πΊπΈ
Minnesota Epilepsy Group, P.A, Saint Paul, Minnesota, United States
πͺπΈCentro MΓ©dico Teknon, Barcelona, Spain
πΊπΈLe Bonheur Children's Hospital, Memphis, Tennessee, United States
EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
- Conditions
- Secondary AML
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT02533115
- Locations
- πΊπΈ
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
πΊπΈNorthside Hospital, Atlanta, Georgia, United States
πΊπΈRush University Medical Center, Chicago, Illinois, United States
A Study of GWP42006 in People With Focal Seizures - Part A
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02369471
A Study of GWP42006 in People With Focal Seizures - Part B
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT02365610
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 239
- Registration Number
- NCT02348593
- Locations
- π¨π¦
Pediatric Sleep Research Inc., Toronto, Ontario, Canada
πΊπΈStanford University Center for Narcolepsy, Redwood City, California, United States
πΊπΈSleep Med of South Carolina, Columbia, South Carolina, United States
"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 174
- Registration Number
- NCT02348619
- Locations
- πΊπΈ
Broward Research Group, Inc., Hollywood, Florida, United States
πΊπΈEmory Sleep Center, Atlanta, Georgia, United States
πΊπΈJohns Hopkins Hospital, Baltimore, Maryland, United States